The “Research Spotlight” series is written by Dr. Anna Berkenblit, PanCAN’s Chief Scientific and Medical Officer. Each month, ...

PanCAN welcomes Jon Mahrt, Chief Executive Officer of Optum Rx and Chief Growth Officer of Optum to the Board of Directors. In this Q&A, Jon shares his personal connection to the cause, his passion ...

A new PanCAN-authored paper uses feedback provided by patients with pancreatic cancer to identify trends in reporting pain.

Pancreatic cancer patients who participate in clinical research have better outcomes. Learn more and search our up-to-date clinical trials database.

Guiding the Pancreatic Cancer Community - Pancreatic Cancer Action Network*PanCAN’s Case Managers are not medical or nutritional professionals and are therefore unable to provide medical/nutritional ...

The Pancreatic Cancer Action Network (PanCAN), the leading nonprofit organization dedicated to [...] READ MORE ...

Learn about the common symptoms of the world’s toughest cancer, such as weight loss, digestive problems, back pain and more.

American Cancer Society’s Cancer Facts & Figures 2023 reports that the five-year survival rate for pancreatic cancer has increased to 12%, progress that PanCAN’s initiatives helped to fuel.

For the first time in more than 10 years, the FDA has approved a new first-line treatment, called NALIRIFOX, for patients with metastatic pancreatic cancer.

Pancreatic cancer is anticipated to become the second leading cause of cancer-related death in the U.S. around 2020. More awareness of this disease must be gained to increase knowledge, action and ...

For the third year in the row, the pancreatic cancer five-year survival rate has increased one percentage point, to 13%, according to the American Cancer Society’s Cancer Facts & Figures 2024 Report.